Advancing best-in-class allogeneic CAR-T therapies

Immuno-Oncology Insights 2023; 4(3), 39–43

DOI: 10.18609/ioi.2023.006

Published: 16 April 2023
Viewpoint
Blair Madison


“Typically, the targeted inactivation (knockout) of key genes is the go-to approach to remove mediators of alloreactivity.”